152 related articles for article (PubMed ID: 30768970)
1. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
Gong Z; Jia Q; Chen J; Diao X; Gao J; Wang X; Zhu B
J Thorac Oncol; 2019 May; 14(5):857-866. PubMed ID: 30768970
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of the immune microenvironment associated with RRM2 expression and its application to PD-L1/PD-1 inhibitors in lung adenocarcinoma.
Lee SK; Hwang Y; Han JH; Haam S; Lee HW; Koh YW
Am J Cancer Res; 2023; 13(11):5443-5454. PubMed ID: 38058821
[TBL] [Abstract][Full Text] [Related]
4. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
McGranahan N; Furness AJ; Rosenthal R; Ramskov S; Lyngaa R; Saini SK; Jamal-Hanjani M; Wilson GA; Birkbak NJ; Hiley CT; Watkins TB; Shafi S; Murugaesu N; Mitter R; Akarca AU; Linares J; Marafioti T; Henry JY; Van Allen EM; Miao D; Schilling B; Schadendorf D; Garraway LA; Makarov V; Rizvi NA; Snyder A; Hellmann MD; Merghoub T; Wolchok JD; Shukla SA; Wu CJ; Peggs KS; Chan TA; Hadrup SR; Quezada SA; Swanton C
Science; 2016 Mar; 351(6280):1463-9. PubMed ID: 26940869
[TBL] [Abstract][Full Text] [Related]
5. Identification of CNKSR1 as a biomarker for "cold" tumor microenvironment in lung adenocarcinoma: An integrative analysis based on a novel workflow.
Cai Q; Peng M
Heliyon; 2024 Apr; 10(8):e29126. PubMed ID: 38628722
[TBL] [Abstract][Full Text] [Related]
6. Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
Wang S; Xie T; Li Y; Guo L; Ying J; Wang Y; Hao X; Wang X; Li J; Xing P
Cancer; 2023 Dec; 129(24):3873-3883. PubMed ID: 37538036
[TBL] [Abstract][Full Text] [Related]
7. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
Yang P; He S; Ye L; Weng H
Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
[TBL] [Abstract][Full Text] [Related]
8. Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.
Luo B; Sun Y; Zhan Q; Luo Y; Chen Y; Fu T; Yang T; Ren L; Xie Z; Situ X; Liu B; Tang K; Ke Z
Clin Transl Med; 2024 Jan; 14(1):e1553. PubMed ID: 38279870
[TBL] [Abstract][Full Text] [Related]
9. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
[TBL] [Abstract][Full Text] [Related]
10. Screening and validation of plasma cell-derived, purinergic, and calcium signalling-related genetic signature to predict prognosis and PD-L1/PD-1 blockade responses in lung adenocarcinoma.
Huang J; Fan X; Hu B; Chen L
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12931-12945. PubMed ID: 37468608
[TBL] [Abstract][Full Text] [Related]
11. A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma.
Fitzgerald B; Connolly KA; Cui C; Fagerberg E; Mariuzza DL; Hornick NI; Foster GG; William I; Cheung JF; Joshi NS
Cell Rep Methods; 2021 Sep; 1(5):. PubMed ID: 34632444
[TBL] [Abstract][Full Text] [Related]
12. System analysis based on glutamine catabolic-related enzymes identifies GPT2 as a novel immunotherapy target for lung adenocarcinoma.
Wang B; Pei J; Xu S; Liu J; Yu J
Comput Biol Med; 2023 Oct; 165():107415. PubMed ID: 37657356
[TBL] [Abstract][Full Text] [Related]
13. An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
Wang Q; Xie B; Sun J; Li Z; Xiao D; Tao Y; She X
J Cancer; 2024; 15(6):1687-1700. PubMed ID: 38370388
[No Abstract] [Full Text] [Related]
14. Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas.
Li B; Guo Y; Yi Y; Huang Z; Ren Y; Wang H; Yang L
J Transl Med; 2023 Sep; 21(1):599. PubMed ID: 37674198
[TBL] [Abstract][Full Text] [Related]
15. Anchoring Filament Protein Ladinin-1 is an Immunosuppressive Microenvironment and Cold Tumor Correlated Prognosticator in Lung Adenocarcinoma.
Yuan K; Zhang Y; Yu Y; Xu Y; Xian S
Biochem Genet; 2023 Oct; 61(5):2173-2202. PubMed ID: 37005975
[TBL] [Abstract][Full Text] [Related]
16. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
Ghorani E; Rosenthal R; McGranahan N; Reading JL; Lynch M; Peggs KS; Swanton C; Quezada SA
Ann Oncol; 2018 Jan; 29(1):271-279. PubMed ID: 29361136
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy.
Zheng X; Li L; Yu C; Yang J; Zhao Y; Su C; Yu J; Xu M
Aging (Albany NY); 2021 Nov; 13(21):24313-24338. PubMed ID: 34762599
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications.
Zhou YJ; Zhu GQ; Lu XF; Zheng KI; Wang QW; Chen JN; Zhang QW; Yan FR; Li XB
Cancer Immunol Immunother; 2020 Jun; 69(6):1057-1069. PubMed ID: 32100076
[TBL] [Abstract][Full Text] [Related]
19. Spatial transcriptomics reveals heterogeneity of histological subtypes between lepidic and acinar lung adenocarcinoma.
Xie L; Kong H; Yu J; Sun M; Lu S; Zhang Y; Hu J; Du F; Lian Q; Xin H; Zhou J; Wang X; Powell CA; Hirsch FR; Bai C; Song Y; Yin J; Yang D
Clin Transl Med; 2024 Feb; 14(2):e1573. PubMed ID: 38318637
[TBL] [Abstract][Full Text] [Related]
20. UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment.
Li Y; Jiang M; Aye L; Luo L; Zhang Y; Xu F; Wei Y; Peng D; He X; Gu J; Yu X; Li G; Ge D; Lu C
Nat Commun; 2024 Feb; 15(1):1200. PubMed ID: 38331898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
